Teriparatide vs Abaloparatide

Both are bone-building PTH1-receptor agonists approved for osteoporosis. Teriparatide is the active fragment of parathyroid hormone; abaloparatide is based on PTH-related protein and favours a different receptor conformation.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Teriparatide

The 1–34 fragment of human parathyroid hormone — the first bone-building (anabolic) osteoporosis medicine.

BEST STUDIED FOR

Repair & immune

Read the cited profile →

🧪

Abaloparatide

A synthetic analogue of parathyroid hormone-related protein (PTHrP 1–34) that selectively activates the PTH1 receptor to build bone.

BEST STUDIED FOR

Repair & immune

Read the cited profile →

SIDE BY SIDE

	Teriparatide	Abaloparatide
The key difference	PTH(1-34)	PTHrP(1-34) analogue
Class	Repair & immune	Repair & immune
Mechanism	Intermittent, once-daily activation of the PTH1 receptor stimulates osteoblasts more than osteoclasts, building new bone; continuous PTH exposure does the opposite.	Abaloparatide shares its first 20 amino acids with PTHrP and favours a receptor conformation linked to transient signalling, which is proposed to give a bone-forming effect with less stimulation of resorption than teriparatide.
Status	Approved for severe osteoporosis in many countries (prescription-only). Head-to-head fracture trials (VERO) and combination studies with denosumab (DATA) are its landmark data.	Approved for postmenopausal osteoporosis (prescription-only); the ACTIVE phase 3 trial measured vertebral fractures.
Reported safety signals	Reviews document hypercalcaemia and dizziness; an osteosarcoma signal in rats led to historical duration limits in labelling.	Reviews and a 2024 meta-analysis report palpitations, dizziness and hypercalcaemia among adverse events.
A key study	VERO compared new fractures with teriparatide versus risedronate in severe postmenopausal osteoporosis. (Lancet 2018, PMID 29129436)	The ACTIVE phase 3 trial measured new vertebral fractures with abaloparatide versus placebo. (JAMA 2016, PMID 27533157)

WHEN TO RESEARCH WHICH

Teriparatide is the reference anabolic bone agent; abaloparatide its PTHrP-based alternative. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Teriparatide] Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial — Lancet 2018. PMID 29129436
[Teriparatide] Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial — Lancet 2013. PMID 23683600
[Teriparatide] Teriparatide: a review — Clin Ther 2004. PMID 15262455
[Abaloparatide] Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial — JAMA 2016. PMID 27533157
[Abaloparatide] The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis — Clin Ther 2024. PMID 38307725
[Abaloparatide] Abaloparatide: A review of preclinical and clinical studies — Eur J Pharmacol 2021. PMID 34364879

FREQUENTLY ASKED

What is the difference between Teriparatide and Abaloparatide?

What is the regulatory status of Teriparatide and Abaloparatide?

Teriparatide: Approved for severe osteoporosis in many countries (prescription-only). Head-to-head fracture trials (VERO) and combination studies with denosumab (DATA) are its landmark data. Abaloparatide: Approved for postmenopausal osteoporosis (prescription-only); the ACTIVE phase 3 trial measured vertebral fractures.

What safety signals have been reported?

Teriparatide: Reviews document hypercalcaemia and dizziness; an osteosarcoma signal in rats led to historical duration limits in labelling. Abaloparatide: Reviews and a 2024 meta-analysis report palpitations, dizziness and hypercalcaemia among adverse events.

Which studies is this comparison based on?

For Teriparatide: “Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial” (PMID 29129436); “Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial” (PMID 23683600); “Teriparatide: a review” (PMID 15262455). For Abaloparatide: “Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial” (PMID 27533157); “The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis” (PMID 38307725); “Abaloparatide: A review of preclinical and clinical studies” (PMID 34364879).